Nicotine replacement therapy (NRT) is a common first-line treatment to prevent nicotine withdrawal in smokers. However, available literature reports conflicting results regarding its efficacy and safety in critically ill patients. The objective of this study was to evaluate the relationship between NRT in smokers in the intensive care unit (ICU) and outcomes. This casecontrol study was conducted in a university-affiliated tertiary hospital ICU. Over a period of five years, 126 active smokers who received transdermal NRT were matched to 126 active smokers who did not receive NRT. The groups were case-matched for sex, age and Acute Physiology and Chronic Health Evaluation II (APACHE II) score. The primary outcome was administration of antipsychotic medication. Secondary outcomes included use of physical restraints, 30-day mortality, and ventilation requirements. Antipsychotic medication was prescribed in 43 (34.1%) patients who received NRT compared to 14 (11.1%) in controls (P <0.01). Physical restraints were used in 37 (29.4%) patients who received NRT, compared to 12 (9.5%) of controls (P <0.01). The 30-day mortality and number of patients intubated was not statistically different between groups. Average length of intubation time was greater in the NRT group (2.56 days; standard deviation 4.16) compared to the control group (1.44 days; standard deviation 2.68) (P=0.012). The use of NRT to prevent nicotine withdrawal in ICU patients is associated with increased use of antipsychotic medication and physical restraint, and with prolonged mechanical ventilation.
Introduction
Approximately 20%-46% of patients admitted to an intensive care unit (ICU) are estimated to be smokers 1 . Nicotine is a major component in tobacco smoke, and chronic administration mediates addiction through up-regulation of nicotinic acetylcholine receptors (nAChRs) 2 . Its agonistic effects on nAChRs augment the release of neurotransmitters including catecholamines, dopamine and γ-aminobutyric acid (GABA). The toxicity of nicotine is systemic, and includes effects on the central nervous system, with also respiratory, cardiovascular, immunologic and gastrointestinal sequelae [3] [4] [5] .
Abrupt smoking cessation may precipitate nicotine withdrawal syndrome, characterised by psychological and physical components. These include bradycardia, anxiety, irritability, agitation, anger, restlessness, craving, confusion, hallucinations, and mood disturbances 2 .
Pharmacological approaches to ameliorate nicotine withdrawal include nicotine replacement therapy (NRT), bupropion, and varenicline 6 . NRT replaces nicotine at a dose compatible with negligible adverse effects while mitigating withdrawal symptoms. NRT is available as transdermal patches, gum, inhaler, spray and lozenges.
NRT is considered appropriate first-line therapy for the prevention of nicotine withdrawal in hospitalised smokers 7, 8 . However, there is limited data regarding the impact of nicotine withdrawal and the safety and efficacy of NRT in critically ill patients admitted to an ICU 1, [9] [10] [11] . We conducted a study to evaluate the effects of NRT administration in smokers in intensive care.
Methods

Design and setting
Our retrospective matched case-control study was undertaken at a tertiary referral ICU in a major teaching hospital in Canberra, Australia. The 31-bed mixed medical/ surgical ICU admits on average 2000 patients per year.
Study population
All patients who were active smokers and received transdermal NRT between 2009 and 2014 were identified and included in the study.
ICU patients who received NRT were matched with control ICU patients based on sex, age, Acute Physiology and Chronic Health Evaluation II (APACHE II) risk of death score, and smoking status. When selecting for age, patients were matched within five years of the experimental patient's age. For APACHE II, control patients were selected based on being in the same category as the experimental patient's score, using their predicted mortality rates.
Ethics approval
This study received ethics approval by the ACT Health Human Research Ethics Committee (ETHLR.14.162).
Data collection
For each patient the following data was collected: patient age, sex, smoking status, APACHE II score, ICU admission diagnosis, NRT status, ventilation status, length of time of ventilation, use of antipsychotic medications, use of dexmedetomidine, use of physical restraint, and 30-day mortality. This data was collected from a number of databases and sources: Metavision (intensive care patient data management system), CRIS database (Canberra Hospital electronic patient records) and Canberra Hospital pharmacy database. For admission dates that pre-dated Metavision, the CRIS database was the primary method of data collection.
The primary outcome for the study was the proportion of patients who received antipsychotic medication, as a surrogate marker for the incidence of agitation and delirium. Secondary outcomes for the study included 30-day mortality, ventilation requirements, length of ventilation time, and use of physical restraint.
The use of antipsychotic medication was defined as the patient receiving any dose of olanzapine, haloperidol or quetiapine during the ICU stay. The use of dexmedetomidine was also collected but not classified as an antipsychotic drug. The use of physical restraint was determined from the doctors' orders section of Metavision, and from nursing records and patient progress notes in CRIS.
ICU admission diagnoses are coded by TCH ICU Research Department. In the NRT group, use of antipsychotic medication, dexmedetomidine and physical restraint was only counted if initiated after commencement of NRT. Patient diagnoses were categorised into 12 categories based on the system involved. These were endocrine, infectious disease, respiratory, renal, cardiology, neurology, oncology, gastroenterology, vascular, trauma, haematology, and other.
Statistical analysis
Data are described as mean (standard deviation, SD) or median (interquartile range, IQR) depending on their distribution. Proportions are described in percentages. For continuous data the results were analysed using Student's t-test. The samples were analysed as though independent and with the assumption of two tails. The Mann-Whitney U test was used when sample data were not normally distributed. For all categorical data the chi-square test and Fisher's exact test were used. Statistical significance was assumed to be a P value less than 0.05. Statistical analysis was performed using SPSS v21 for Windows.
Results
Baseline characteristics
On average, 250 active smokers per year were admitted to the ICU, which translated to approximately 12.5% of all ICU admissions. Through the hospital pharmacy database, we identified 126 patients who received NRT. We matched 126 control patients from the group of active smokers who did not receive NRT. There were no missing data for any of the included patients. NRT was delivered via transdermal patches in all patients. The two groups were well matched for age, sex, and APACHE II score (Table 1 ). There was imbalance between groups for admission diagnoses, with more patients in the cardiology admission category in the control group. However, the distribution of elective versus emergency admissions was not statistically different between groups (Table 1 ).
Outcome parameters
The main outcome parameters are described in Table 2 . A significantly larger number of intensive care patients who received NRT were prescribed antipsychotic medication as compared with controls (34.1% versus 11.1%, P <0.01). Figure 1 shows the distribution of antipsychotic medication administration in both patient groups. Patients in the NRT group also required physical restraint more frequently compared with controls (29.4% versus 9.5%, P <0.01). Patients in the NRT group were intubated for significantly longer than the control group (2.56 versus 1.44 days, P=0.012). In terms of the proportion of patients ventilated there was no significant difference between the two groups (56.3% versus 54.8%, P=0.81). There was no significant difference in the 30-day mortality rates between the two groups (7.1% versus 9.5%, P=0.49). Finally, the use of dexmedetomidine was not significantly different between the two groups (0.8% versus 1.6%, P=0.34).
Discussion
In our study, NRT use in smokers admitted to ICU was associated with an increased risk of agitation and delirium, as indicated by greater use of antipsychotic medication and physical restraint. In addition, smokers who received NRT were intubated for a longer period of time compared with smokers who did not receive NRT. These differences did not translate into a significant difference in 30-day mortality rates between the groups, but the study was not powered to detect a mortality difference.
Admission to the ICU represents a period of enforced abstinence from tobacco smoking. Critically ill patients are commonly unstable and experience significant physical and psychological stressors 11 . Sudden nicotine abstinence in these patients has been linked to the development of delirium and agitation 1, 11 . ICU delirium has been associated with adverse outcomes such as increased rate of self-catheter removal, prolonged length of stay, greater use of sedatives, use of physical restraint to prevent injury, and increased overall mortality 1,10-12 .
NRT therapy has proven to be effective in hospitalised patients and has also been shown to improve smoking cessation rates post-hospital discharge 8 . Extrapolating from this and other research, it has been suggested that the use of NRT in ICU patients may mitigate the effects of nicotine withdrawal and improve patient outcomes, with shorter duration of mechanical ventilation, shorter ICU stay, and reduced use of sedation and analgesics. However, studies specifically addressing nicotine withdrawal in critically ill smokers are scarce, and current literature reports conflicting results concerning the efficacy and safety of NRT in critically ill patients. For example, in a comparable retrospective case-control study in 180 patients, NRT was associated with increased hospital mortality in critically ill patients 9 . In a prospective observational cohort study in 330 critically ill patients, NRT was not associated with increased hospital mortality; however, no clinically significant benefit could be demonstrated either 13 . Another retrospective case-control study was unable to demonstrate any harm associated with NRT use in critically ill patients 14 .
Nicotine withdrawal syndromes are not well characterised in ICU patients, who often have complex physiological disturbances with haemodynamic instability and multiple organ dysfunction. Due to these confounding factors, it is difficult to determine the exact incidence of nicotine withdrawal in ICU patients, and therefore the efficacy of treatments designed to reduce withdrawal symptoms. In a recent systematic review addressing NRT in the ICU, the authors reported equivocal evidence of efficacy and signals suggesting increased toxicity, and recommended NRT use should be limited to selected patients where the potential benefit outweighs the risks 15 .
The mechanisms by which NRT may cause adverse health outcomes in ICU patients are not well understood. Patients in the ICU differ from other patients in many ways. Firstly, it is currently unknown whether absorption and distribution of NRT administered through a transdermal delivery system is affected in critically ill patients. Secondly, sympathomimetic effects of nicotine may adversely impact on already compromised patients with complex abnormal physiology. The haemodynamic effects of nicotine include increased heart rate, blood pressure and myocardial contractility. Increasing myocardial oxygen consumption during times of reduced oxygen delivery may be detrimental in critically ill patients. In addition, NRT may have different effects in different ICU populations, such as trauma, surgical, or cardiovascular patients. Some recent studies analysing the efficacy of NRT in ICU subpopulations have raised the possibility that NRT may have system-specific effects. For example, beneficial and harmful outcomes have been demonstrated in subarachnoid haemorrhage and postcoronary bypass graft patient groups, respectively 16, 17 . Our finding of an increased requirement of antipsychotic drugs and physical restraint in the NRT group compared to controls is consistent with the results of a prospective observational cohort study 13 . This finding is important, but has to be interpreted with caution. Although it is biologically plausible that NRT causes delirium in critically ill patients, the presence of delirium or of additional risk factors for the development of delirium, may have made NRT more likely to be applied by the treating clinician. However, even if the latter is the case, then NRT is still unlikely to be an effective treatment for agitation and delirium in this setting according to our results. An alternative explanation would be underdosing of NRT, which cannot be easily confirmed or refuted. This would perhaps explain a lack of efficacy in terms of preventing withdrawal symptoms, but would not explain an increase in agitation and delirium frequency compared to smokers who did not receive NRT. Baseline imbalances could have contributed to the differences observed. The groups were well matched for age, gender, severity of disease, and elective versus emergency admission, but not for admission diagnosis group. In addition, we were unable to assess smoking history, nor collect information regarding preadmission alcohol or other psychoactive drug use. This may have resulted in an unmeasured baseline imbalance. Of note, NRT use in our ICU was generally very low. Of approximately 1,250 active smokers admitted to the ICU over the study period, only 126 (10.1%) were prescribed NRT. This low prescribing rate may indicate further selection bias caused by unknown prescribing preferences. Finally, our study is a single-centre retrospective study, which limits validity and generalisability.
Conclusion
In conclusion, consistent with previous reports, we found possible harm associated with the use of NRT in ICU patients. We suggest that NRT in ICU patients should not be used outside rigorously conducted clinical trials designed to assess safety and efficacy in this vulnerable and complex patient group. Given the widespread uptake of NRT in hospitalised patients, we believe that a large prospective trial is needed.
